AVDL Avadel Pharmaceuticals ADS

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit .

Investor Contact:

Austin Murtagh

Precision AQ



(212) 698-8696

Media Contact:

Lesley Stanley

Real Chemistry



(609) 273-3162



EN
01/04/2025

Underlying

AVDLAvadel Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avadel Pharmaceuticals ADS

 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcar...

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference. About Av...

April 1, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key...

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a titled “A New Dawn in the Management of Narcolepsy”. “I am delighted to serve as guest editor for the recently publi...

March 25, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be availab...

March 5, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Q...

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results -- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enr...

March 3, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth...

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by v...

February 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch